Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort
| Autor: | Michael Halberthal, Yael Shachor-Meyouhas, Gila Hyams, Michal Mekel, Marielle Kaplan, Moran Szwarcwort-Cohen, Khetam Hussein, Netanel A. Horowitz, Avi Weissman, Halima Dabaja-Younis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Article Serology Internal medicine medicine Dose effect Healthcare workers Humans Seroconversion Positive serology BNT162 Vaccine COVID-19 coronavirus disease 2019 Aged Retrospective Studies Pfizer BNT162b2 Vaccines General Veterinary General Immunology and Microbiology business.industry SARS-CoV-2 HMO(s) health maintenance organization(s) Public Health Environmental and Occupational Health COVID-19 Retrospective cohort study Middle Aged HCW healthcare workers Vaccination CI confidence interval OR odds ratio Infectious Diseases Cohort Molecular Medicine Female MOH ministry of health business |
| Zdroj: | Vaccine |
| ISSN: | 1873-2518 0264-410X |
| Popis: | Introduction The coronavirus disease 2019 (COVID-19) pandemic has led to worldwide vaccination development efforts. In December 2020 the Pfizer BNT162b2 vaccine was approved in the United States. This study describes the first BNT162b2 vaccine dose effect on a large cohort. Methods This retrospective study examined first vaccine dose effect on serology and investigated the associations between seroconversion and age or sex. Results Serological blood tests were performed on 1898 participants following first vaccine dose; 81% were tested on day 21, before receiving the second dose (mean age 47.5 ± 12.45; median 47.7, range 18–90). Positive serology was found in 92.7% of day 21 tests. Overall positivity was 86.8%, with rates increasing from 2.5% within 1–14 days to 89.8% (14–20 days), 92.7% (21 days), and 95.9% (>21 days). Mean antibody levels 21 days after first dose were 64.3 ± 33.01 AU/ml, (range 15–373 AU/ml, median 61 AU/ml). Seropositivity was greater in females than males (88.3%. vs 83.3% respectively, p 60 years was associated with decreased likelihood of seropositivity (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect